NRx Pharmaceuticals To Host Conference Call And Q&A Session On August 10 To Discuss FDA's Completion Of First-Cycle Review Of Its ANDA For Preservative-Free Ketamine
Benzinga Newsdesk 2 months ago
News
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA's completion of first-cycle review of the Company's ANDA for preservative-free ketamine, announced earlier today.
Participating on the call will be Jonathan Javitt, MD, MPH, Founder and Chief Executive Officer; Glenn Tyson, Chief Commercial Officer; and Chaim Hurvitz, Director, former director of Teva and President of the Teva International Group. Questions will cover both the regulatory path to approval and the Company's commercial plans.